Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00698646 · ClinicalTrials.gov registry record · Phase 4

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.

A Phase 4 study, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 4
Development phase
384
Enrollment target

NCT00698646: Completed Phase 4 study, sponsored by Novartis Pharmaceuticals.

NCT00698646 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 384 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00698646, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 4
Development phase
384 participants
Enrollment target

Study Summary

The purpose of the study is to evaluate the safety and efficacy of initial treatment therapy with valsartan/hydrochlorothiazide (HCTZ) versus the initial treatment therapy with monotherapies (valsartan or HCTZ) in the very elderly patients (greater than or equal to 70 years) with stage 1 or 2 hypertension

Interventions

  • DRUG Valsartan
  • DRUG HCTZ
  • DRUG Valsartan + HCTZ

Trial Details

FieldValue
Enrollment Target 384 participants
Start Date 2008-04
Est. Completion 2009-06
Phase Phase 4
Novartis Pharmaceuticals

1,375 total trials

What the finished NCT00698646 record still lists

NCT00698646 is an interventional study that assigns participants to a tested intervention. The registered 384 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (26% lower).

The record links to 0 conditions, and to 3 interventions - of which Valsartan is the first listed.

NCT00698646 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00698646 about?

NCT00698646 is a clinical study titled "Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.". The purpose of the study is to evaluate the safety and efficacy of initial treatment therapy with valsartan/hydrochlorothiazide (HCTZ) versus the initial treatment therapy with monotherapies (valsartan or HCTZ) in the very elderly patients (greater than or equal to 70 years) with stage 1 or 2 hypert...

What is the current status of trial NCT00698646?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 384 participants. The study started on 2008-04. Estimated completion is 2009-06.

What interventions are being tested in trial NCT00698646?

The interventions under investigation include: Valsartan (DRUG), HCTZ (DRUG), Valsartan + HCTZ (DRUG).

Who is sponsoring clinical trial NCT00698646?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00698646's enrollment target sits among peer trials

384 222nd of 2000 higher than 1,779 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06277661 · 384 participants · NA

    The Mom and Infant Outcomes (MOMI) Study

  • NCT06372964 · 384 participants · Phase 3

    Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

  • NCT06501040 · 384 participants · NA

    Increasing Knowledge and Interest in Cancer Clinical Trials

  • NCT06566703 · 384 participants · NA

    Testing ANSOS for Efficacy in Multi-Tribal Urban Communities

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00698646, the US trial registry maintained by the National Library of Medicine. NCT00698646 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.